Welltower Price Target Raised to $215 with Q4 Growth and $11B Investments
Morgan Stanley raised its price target on Welltower to $215 from $200 and maintained an overweight rating after Q4 revenue rose 36%, EBITDA gained 32% and FFO per share rose 22%. The company completed $11 billion investments funded by a $7.2 billion outpatient sale, booking $5.7 billion in early 2026 acquisitions.
1. Price Target Increase
Morgan Stanley raised its 12-month price target on Welltower to $215 from $200 and maintained an overweight rating, reflecting confidence in the company’s accelerating growth trajectory.
2. Q4 Financial Results
In Q4, Welltower reported 36% revenue growth, a 32% increase in EBITDA and a 22% rise in FFO per share, marking a pivotal performance gain over the prior year.
3. Strategic Divestiture and Reinvestment
The company sold its outpatient medical business for $7.2 billion, redeploying capital into senior housing markets and launching its private funds management business to enhance long-term returns.
4. Strong Start to 2026 Investments
In the first six weeks of 2026, Welltower booked $5.7 billion in acquisitions and holds a further $2.5 billion in potential deals, underscoring robust deal flow momentum.